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Excessive ethanol exposure can cause mitochondrial and cellular toxicity. In order to
discover potential counteracting interventions, it is essential to develop assays capable
of capturing the consequences of ethanol exposure in human neurons, and particularly
dopaminergic neurons that are crucial for the development of alcohol use disorders
(AUD). Here, we developed a novel high-throughput (HT) assay to quantify mitochondrial
and neuronal toxicity in human dopaminergic neuron-containing cultures (DNs) from
induced pluripotent stem cells (iPSCs). The assay, dubbed mitochondrial neuronal health
(MNH) assay, combines live-cell measurement of mitochondrial membrane potential
(MMP) with quantification of neuronal branching complexity post-fixation. Using the
MNH assay, we demonstrated that chronic ethanol exposure in human iPSC-derived
DNs decreases MMP and neuronal outgrowth in a dose-dependent manner. The toxic
effect of ethanol on DNs was already detectable after 1 h of exposure, and occurred
similarly in DNs derived from healthy individuals and from patients with AUD. We
next used the MNH assay to carry out a proof-of-concept compound screening using
FDA-approved drugs. We identified potential candidate compounds modulating acute
ethanol toxicity in human DNs. We found that disulfiram and baclofen, which are used for
AUD treatment, and lithium caused neurotoxicity also in the absence of ethanol, while
the spasmolytic drug flavoxate positively influenced MNH. Altogether, we developed
an HT assay to probe human MNH and used it to assess ethanol neurotoxicity and
to identify modulating agents. The MNH assay represents an effective new tool for
discovering modulators of MNH and toxicity in live human neurons.
Keywords: iPSCs, neurons, mitochondria, ethanol, high-content screening, neuronal toxicity
INTRODUCTION
Ethanol is the most frequently abused drug worldwide and its excessive consumption is a leading
risk factor for disability and death (Griswold et al., 2018). High ethanol consumption over
time can lead to serious health and social problems, including the development of alcohol use
disorder (AUD). AUD is among the most prevalent mental disorders in industrialized countries
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 November 2020 | Volume 8 | Article 590540
fcell-08-590540 October 30, 2020 Time: 15:48 # 2
Zink et al. High-Throughput Mitochondrial Neuronal Health Assay
(Kessler et al., 2005). Once ingested, ethanol quickly distributes
throughout the body and reaches the brain within minutes.
Given this rapid and vast spread, ethanol can cause direct
organ toxicity. Ethanol-induced neurotoxicity is particularly
detrimental given that damaged neurons cannot be replaced.
Within the central nervous system, ethanol exposure directly
affects dopaminergic neurons, resulting in increased extracellular
dopamine mainly in the striatum (Heinz et al., 2011), higher
firing frequency and increased excitability (Trantham-Davidson
and Chandler, 2015), as well as decreased dopamine synthesis
and dopamine D2 receptor availability in AUD patients
(Morikawa and Morrisett, 2010).
At the cellular level, an important role during ethanol
intoxication may be played by mitochondria, crucial organelles
that safeguard cellular homeostasis. Mitochondria provide
energy in the form of ATP through oxidative phosphorylation
(OXPHOS), which turns ADP into ATP by releasing the energy
stored in the proton gradient also known as mitochondrial
membrane potential (MMP) (Vafai and Mootha, 2012).
Mitochondria are also crucial for cell death (Dyall et al., 2004).
Selective MMP permeabilization activates caspase-driven
apoptotic cell death through opening of the mitochondrial
permeability transition pore (Tait and Green, 2013). MMP is thus
an essential parameter for viable cells, since it is important for
both ATP generation and initiation of apoptosis, and may serve
as a marker of cell health (Chen, 1988). Various studies reported
ethanol-induced toxicity in mitochondria located in the brain
(Manzo-Avalos and Saavedra-Molina, 2010), including increased
mitochondrial production of free radicals (Reddy et al., 2013),
alterations in mitochondrial respiration and MMP (Haorah
et al., 2013; Reddy et al., 2013), impairment of ATP production
(Bustamante et al., 2012; Jung, 2015), and cell death induction
(Lamarche et al., 2013; Jung, 2015).
The mechanisms underlying ethanol-induced toxicity in
human brain cells remain largely unknown. Most investigations
are based on animal models, which may not fully recapitulate
the human disease, or on post-mortem tissues, which correlates
more to an end-stage of AUD, or on brain imaging, which
provides macroscopic data lacking information at the cellular
and molecular level (Goldman, 2016). Given the lack of
suitable human cell-based model systems for the assessment of
neurotoxicity and drug discovery, our knowledge of compounds
capable of counteracting ethanol toxicity in humans is limited.
Here, we used human induced pluripotent stem cells (iPSCs)
to investigate the toxic consequences of ethanol in human
neuronal cultures containing dopaminergic neurons. In order
to assess human neurotoxicity in a quantitative and high-
throughput (HT) manner, we devised a new assay that we
named mitochondrial neuronal health (MNH) assay. The MNH
assay is based on high-content imaging (HCI) and combines
live-cell measurement of MMP with quantification of neuronal
branching outgrowth. Using this assay, we demonstrated the
acute and chronic effects of ethanol toxicity on MNH in
human dopaminergic neuron-containing cultures (DNs), which
we derived from iPSCs from healthy individuals and subjects
with AUD. We also showed that the MNH assay can be used
to perform compound screenings to identify drugs influencing
MNH. Altogether, the newly developed MNH assay represents
an effective HT tool for analyzing the cellular health of
human iPSC-derived neurons and for discovering potential
modulatory interventions.
RESULTS
Development of the MNH Assay
In order to assess the toxic effects of ethanol in human
neurons, we first generated neural progenitor cells (NPCs)
from healthy control-derived iPSCs (XM001 line) (Wang et al.,
2018) and human embryonic stem cells (hESCs) (H1 line)
(Thomson et al., 1998) using a small molecule-based protocol
(Reinhardt et al., 2013). We then differentiated NPCs into post-
mitotic neuronal cultures enriched for dopaminergic neurons,
which we further refer to as dopaminergic neuron-containing
cultures (DNs) (Figure 1A). The pluripotent stem cell-derived
DNs expressed the neuron-specific marker MAP2 and the
dopaminergic markers tyrosine hydroxylase (TH) and FOXA2
(Figure 1B). In the differentiated cultures, 75% of cells expressed
the pan-neuronal marker beta tubulin-III (TUJ1) and 20%
expressed TH (Figure 1C). These numbers are in accordance
with previous protocols (Burbulla et al., 2017). We monitored
neuronal network activity using micro-electrode array (MEA).
We confirmed that the generated DNs were functional and
exhibited multiple spontaneous spikes after 4–8 weeks in
culture (Figure 1D).
We next established an HCI-based approach to assess
mitochondrial function and neuronal growth capacity in DNs.
We dubbed the method MNH assay. To assess neuronal
branching capacity, we cultivated DNs for 4–8 weeks, re-plated
them on the assay plate and kept them for 1 day or 5 days after
plating. We then fixed the cultures and stained them with TUJ1 to
visualize neuronal arborization (Figure 1E). Since TUJ1 staining
does not allow to discriminate between axons and dendrites, we
chose to refer to any projection from the cell body as neurite. In
order to assess differences in neurite outgrowth, we compared
DNs fixed 1 day or 5 days post-plating to NPCs fixed 1-day
post-plating (Figure 1F). The MNH assay effectively captured
and quantified differences in neuronal outgrowth. DNs at 5 days
post-plating showed increased neurite count (Figure 1G), neurite
length (Figure 1H), and branch points (Figure 1I) compared to
neurons at day 1 post-plating or NPCs at day 1 post-plating. The
cellular population also appeared more homogenous in day 5
DNs, as indicated by lower variability in the distribution of the
replicates (Figures 1G–I).
In order to assess MMP, we implemented an HCI assay
that we previously established for iPSC-derived NPCs (Lorenz
et al., 2017). We measured MMP using the potentiometric
fluorescent dye tetramethylrhodamine methyl ester (TMRM), a
lipophilic cation that accumulates in the mitochondrial matrix
in proportion to the potential of the membrane. We re-
plated 4- to 8-week-old DNs on the assay plate and kept
them for 5 days before live-staining for MMP and subsequent
neuronal branching quantification (Figure 2A). Stimulation with
the OXPHOS uncoupler FCCP and the complex III inhibitor
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FIGURE 1 | Generation of functional DNs and HCI-based neuronal profiling. (A) Schematics of the iPSC-based generation of NPCs and DNs, indicating the
time-points of different media formulations. (B) 4- to 8-week-old DNs generated from control iPSCs (XM001 line) expressed the neuronal marker TUJ1 and MAP2,
and the DA-specific markers FOXA2 and TH. Scale bar: 100 µm. (C) HCI-based quantification of control DNs (XM001) expressing TUJ1 and TH at 8 weeks of
culture (mean ± SEM). Each dot represents mean values (% neuronal cells) from one well. (D) Representative recordings (spike plot and wave plot) of network-based
electrophysiological properties of control DNs after 8 weeks in culture using MEA. (E) Schematic workflow of HCI-based neuronal profiling analysis.
(F) Representative images of NPCs and DNs (at 4–8 weeks of differentiation) fixed after day 1, and of DNs fixed after day 5. Cell bodies depicted in blue, branch
points in yellow, neurites in green, and cross points in magenta. All images were taken at 10× magnification. (G–I) Quantification of neurite count (G), neurite length
(H), and branch points (I) in NPCs and 4- to 8-week-old DNs at day 1 and day 5 after re-plating (30 technical replicates for DNs and 60 technical replicates for
NPCs; each dot represents the value obtained from one well; mean ± SEM; ***p < 0.001; one-way ANOVA followed by Dunnett’s multiple comparison test).
Antimycin A (Ant.A) provoked a dose-dependent decrease in
the MMP (Figure 2B), whereas the ATPase inhibitor Oligomycin
led to a dose-dependent increase in the MMP (Figure 2C). The
MMP-modulating effects of the mitochondrial inhibitors are in
line with previous works (Kalbácová et al., 2003; Li et al., 2014).
The use of stimulating and inhibiting MMP modulators enabled
us to determine the z-factor, a statistical indicator of HT bioassays
that is considered excellent if 0.5 > x > 1 (Zhang et al., 1999).
The MNH assay had a z-factor of 0.747, suggesting excellent
features regarding reproducibility and robustness (Figure 2C).
Branching complexity did not change upon exposure to FCCP
and Ant.A at a concentration of up to 100 µM (Figures 2D–F), or
to oligomycin at a concentration of up to 200 µM (Figures 2G–I).
Taken together, the MNH assay was able to quantitatively
identify changes in neuronal outgrowth capacity and in MMP-
specific function.
The MNH Assay Detects Chronic and
Acute Ethanol-Induced Toxicity in
Human Neurons
In alcohol-naïve individuals, blood alcohol concentrations
(BACs) of 10–50 mM typically lead to sedation, motor
incoordination, and cognitive impairment, and BACs of
≥100 mM cause strong sedation and can lead to coma or death
(Adinoff et al., 1988). In contrast, BACs up to 300 mM have been
reported in chronic alcohol consumers (Johnson et al., 1982),
where 100–200 mM typically lead to sedation, anxiolysis, and
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FIGURE 2 | MNH assay development. (A) Schematics of the MNH assay. (B) Quantification of MMP in 4- to 8-week-old DNs derived from hESCs (H1 line) treated
with increasing concentrations of FCCP and Ant.A (0.005–200 µM). Each dot represents the average of the values obtained from one well normalized to the
corresponding untreated (UT) control exposed to the assay media only (n = 3 independent experiments; mean ± SEM; ***p < 0.001; one-way ANOVA followed by
Dunnett’s multiple comparison test). (C) Quantification of MMP in 4- to 8-week-old DNs from control hESCs (H1 line) treated with increasing concentrations of
oligomycin (0.005–200 µM; mean ± SEM; *p < 0.05, ***p < 0.001; one-way ANOVA followed by Dunnett’s multiple comparison test). Each dot represents the
average of values obtained from one well normalized to the corresponding UT control exposed to the assay media only (n = 3 independent experiments).
Assessment of the z-factor of 0.747 obtained at 200 µM FCCP and 200 µM Ant.A versus 200 µM Oligomycin suggesting an excellent assay. (D–F) Quantification of
neurite count (D), neurite length (E), and branch points (F) in 4- to 8-week-old DNs from hESCs (H1 line) treated with increasing concentrations of FCCP and Ant.A
(0.005–200 µM; mean ± SEM; *p < 0.05; one-way ANOVA followed by Dunnett’s multiple comparison test). Each dot represents values obtained from one well
(n = 3 independent experiments), normalized to the corresponding UT controls exposed to the assay media only. (G–I) Quantification of neurite count (G), neurite
length (H), and branch points (I) in 4- to 8-week-old DNs from hESCs (H1) treated with increasing concentrations of oligomycin (0.005–200 µM; mean ± SEM;
*p < 0.05; one-way ANOVA followed by Dunnett’s multiple comparison test). Each dot represents values obtained from one well (n = 3 independent experiments),
normalized to the corresponding UT controls exposed to the assay media only.
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hypnosis (Abrahao et al., 2017; Cui and Koob, 2017). For in vitro
studies, the 10–100 mM ethanol range is therefore appropriate,
and the addition of ethanol to cell cultures has been reported in
the 1–500 mM range (Dolganiuc and Szabo, 2009). However, it is
not clear at which concentrations ethanol can cause toxicity in
human neuronal cultures.
To address the toxic effects of ethanol on human DNs, we
tested healthy DNs after 4–8 weeks of differentiation from iPSCs
(XM001 line) and hESCs (H1 line). We exposed healthy DNs
to different concentrations of ethanol in the media for 7 days
(chronic exposure), with full media exchange every other day
(Figure 3A). In our experimental setting, ethanol evaporation
may occur inside the incubator during the exposure. This
means, that the final ethanol concentration on the DNs may
be lower than the one measured before the exposure. Chronic
exposure to ethanol over 7 days increased MMP at ethanol
concentrations of 10–100 mM and caused the MMP to collapse
at ethanol concentrations ≥500 mM (Figure 3B). Ethanol
concentrations higher than 250 mM also strongly impaired
neurite outgrowth (Figures 3C–E).
We next investigated whether changes in MNH could also
occur in DNs after short acute exposure to ethanol. We plated
4- to 8-week-old DNs generated from iPSCs (XM001) and hESCs
(H1) on the assay plate, kept them for 5 days and then exposed
them to ethanol for 1 h before the assay (Figure 3F). We observed
the occurrence of apoptotic cell death (assessed by Annexin V
staining) only in DNs exposed to 2.5 M ethanol concentration
(Figure 3G). Hence, in our settings DNs retained viability even
after exposure to relatively high concentrations of alcohol. Acute
ethanol exposure led to a dose-dependent reduction of MMP
starting at concentrations of 500 mM ethanol in DNs derived
from iPSCs (Figure 3H) and hESC-derived DNs (Figure 3L).
Acute ethanol exposure caused a dose-dependent reduction in
neurite count starting at 250 mM ethanol in DNs derived from
iPSCs (Figure 3I) and at 500 mM ethanol in DNs derived
from hESCs (Figure 3M). Neurite length decreased starting
from 500 mM ethanol in DNs derived from iPSCs (Figure 3J)
and hESCs (Figure 3N). A dose-dependent decrease in branch
points was observed at ≥500 mM ethanol in DNs derived from
iPSCs (Figure 3K) and at ≥1 M ethanol in DNs derived from
hESCs (Figure 3O).
Altogether, using the MNH assay to quantify ethanol-induced
neurotoxicity, we determined that both acute and chronic
exposure to ethanol negatively affected human MNH. MMP and
branching defects occurred for ethanol concentrations lower than
those needed to elicit apoptotic cell death. The findings suggest
that ethanol-induced toxicity in human neurons happens very
rapidly, and that the MNH assay is able to capture early toxic
states that are not yet causing widespread cell death.
Neurons From AUD Patients
Recapitulate Acute Ethanol-Induced
Neurotoxicity
Next, we aimed to address ethanol-induced neurotoxicity in
DNs derived from individuals diagnosed with AUD according
to DSM-5 and ICD-10 (alcohol dependence). Using Sendai
virus-mediated reprogramming, we generated iPSCs from four
AUD patients: BIH232, BIH234, BIH235, and BIH236. All AUD-
iPSCs expressed the pluripotency-associated protein markers
OCT4 and TRA1-60 (Figure 4A). Compared to somatic
fibroblasts, AUD-iPSCs exhibited higher mRNA expression
of the pluripotency-associated gene markers OCT4, NANOG,
SOX2, DNMT3B, and DPPA4, and lower expression of the
fibroblast-associated gene marker VIM (Figure 4B). The
AUD-iPSCs had normal karyotypes (Figure 4C) and were
pluripotent as they were capable of generating cells belonging
to the three germ layers: endoderm, mesoderm, and ectoderm
(Figure 4D). We then differentiated AUD-iPSCs into NPCs
and DNs. AUD-NPCs expressed the NPC-associated markers
NESTIN and PAX6 (Figure 5A). AUD-DNs expressed the pan-
neuronal protein marker TUJ1 and the dopaminergic neuron
marker TH (Figure 5A).
We used the MNH assay to quantify changes in MMP and
neuronal arborization in AUD-DNs following 1 h of acute
ethanol exposure (Figure 5B). Acute ethanol exposure decreased
MMP in AUD-DNs as observed in healthy DNs, but only at
high concentrations of 1 M and 2.5 M ethanol for lines BIH232
(Figure 5C) and BIH236 (Figure 5O), and 2.5 M ethanol for
lines BIH234 (Figure 5G) and BIH235 (Figure 5K). Acute
ethanol exposure also caused a dose-dependent reduction of
neurite outgrowth requiring higher ethanol concentrations in
AUD-DNs than in healthy DNs, starting at 1 M ethanol for
neurite count (Figures 5D,H,L,P), 500 mM–1 M ethanol for
neurite length (Figures 5E,I,M,Q), and 500 mM–1 M ethanol for
branch points (Figures 5F,J,N,R).
Taken together, acute ethanol exposure negatively affected
MNH in AUD-derived DNs. The individual AUD lines showed
some level of heterogeneity, which may reflect different
susceptibility to alcohol toxicity in different subjects.
MNH-Based Proof-of-Concept
Compound Screening Identified
Modulators of Ethanol Neurotoxicity
We next sought to determine whether the MNH assay could be
used to carry out compound screenings to identify modulators
of neurotoxicity. For screening, we used DNs derived from
control iPSCs (XM001 line), which are more sensitive to ethanol
than AUD-DNs. We focused our attention on acute ethanol
exposure, which may still be potentially reversible. Using a library
containing 700 FDA-approved drugs (Selleckchem # z65122),
we selected 48 compounds that are approved for clinical use
in the context of brain diseases (compound numbers 1–48;
Figures 6B–D and Appendix Table 1). Additionally, we included
five drugs that are used for the treatment of AUD patients
(compound numbers 49–53; Figures 6B–D and Appendix
Table 1).
We plated 4- to 8-week-old DNs and cultured them for
5 days. We treated DNs overnight (ON) with 0.5 µM of each of
the 53 compounds in a proof-of-concept experiment. We then
exposed DNs to 1 M ethanol for 1 h and performed the MNH
assay (Figure 6A). Total object count, obtained by quantifying
Hoechst-stained nuclei, showed no significant changes in cell
number following the compound treatments, suggesting that we
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FIGURE 3 | Chronic and acute ethanol exposure leads to decreased MMP and reduced branching complexity in iPSC-derived DNs. (A) Schematic of MNH assay
workflow for chronic (7 days) ethanol exposure. (B) Quantification of the MMP in 4- to 8-week-old DNs from control iPSCs (XM001) exposed for 7 days (chronic) to
increasing concentrations of ethanol (10 mM–2.5 M; mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA followed by Dunnett’s multiple comparison
test). Each dot represents values obtained from one well (n = 3 independent experiments), normalized to the corresponding UT controls exposed to the assay media
only. (C–E) Quantification of the neuronal branching complexity including neurite count (C), neurite length (D), and branch points (E) in 4- to 8-week-old DNs from
control iPSCs (XM001) exposed to increasing concentrations of ethanol for 7 days (chronic treatment) (10 mM–2.5 M; mean ± SEM; ***p < 0.001; one-way ANOVA
followed by Dunnett’s multiple comparison test). Each dot represents values obtained from one well (n = 3 independent experiments) normalized to the
corresponding UT controls exposed to the assay media only. (F) Schematic of MNH assay workflow of ethanol exposure for 1 h (acute treatment). (G) Quantification
of apoptosis via Annexin-V intensity on 4- to 8-week-old DNs from control iPSCs (XM001) exposed to ethanol for 1 h (mean ± SEM ***p < 0.005; one-way ANOVA
followed by Dunnett’s multiple comparison test). Control wells included untreated DNs (UT) and DNs treated with 1 µM staurosporine for 1.5 h as a positive control
for apoptosis. Each dot represents values obtained from one well (n = 4 independent experiments) normalized to UT controls exposed to the assay media only.
(Continued)
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FIGURE 3 | Continued
(H) Quantification of MMP in 4- to 8-week-old DNs from control iPSCs (XM001) exposed to increasing concentrations of ethanol for 1 h (acute treatment;
mean ± SEM; *p < 0.05, ***p < 0.001; one-way ANOVA followed by Dunnett’s multiple comparison test). Each dot represents values obtained from one well (n = 3
independent experiments) normalized to UT controls exposed to the assay media only. (I–K) Quantification of neuronal profiling including neurite count (I), neurite
length (J), and branch points (K) in 4- to 8-week-old DNs from control iPSCs (XM001) exposed to increasing concentrations of ethanol for 1 h (acute exposure)
(mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA followed by Dunnett’s multiple comparison test). Each dot represents values obtained from one
well (n = 3 independent experiments) normalized to the corresponding UT controls exposed to assay media only. (L) Quantification of the MMP in 4- to 8-week-old
DNs from hESCs (H1 line) exposed to increasing concentrations of ethanol for 1 h (acute exposure; mean ± SEM; ***p < 0.001; one-way ANOVA followed by
Dunnett’s multiple comparison test). Each dot represents values obtained from one well (n = 3 independent experiments) normalized to the corresponding UT
controls exposed to the assay media only. (M–O) Quantification of neuronal profiling including neurite count (M), neurite length (N), and branch points (O) in 4- to
8-week-old DNs from hESCs (H1 line) exposed to increasing concentrations of ethanol for 1 h (acute treatment; mean ± SEM; *p < 0.05, ***p < 0.001; one-way
ANOVA followed by Dunnett’s multiple comparison test). Each dot represents values obtained from one well (n = 3 independent experiments) normalized to the
corresponding UT controls exposed to the assay media only.
could confidently compare treated samples to untreated samples
(Figure 6B). As baseline for comparisons, we used DNs treated
for 1 h with 1 M ethanol that were not pre-exposed to any
compound (Figures 6C,D, red dot and black horizontal line).
We defined a compound as a “positive hit” for MMP or neurite
count when the compound led to values that were at least 0.5
times higher than the standard deviation (SD) of neurons only
exposed to ethanol (Figures 6C,D, light blue dots and light green
dots). We defined a compound as a “negative hit” for MMP or
neurite count when the compound led to values that were at least
0.5 times lower than the SD of neurons only exposed to ethanol
(Figures 6C,D, dark blue dots and dark green dots).
Twelve positive hit compounds increased the MMP in the
presence of ethanol (Figure 6C, light blue dots), and four
positive hit compounds increased the number of neurites in the
presence of ethanol (Figure 6D, light green dots). Two positive
hit compounds ameliorated both the MMP and neurite count,
namely flavoxate and tripelennamine (Figure 6E).
Twenty-nine negative hit compounds decreased the MMP
further than ethanol alone (Figure 6C, dark blue dots),
and 33 negative hit compounds decreased the neurite count
further (Figure 6D, dark green dots). Twenty-one negative
hit compounds decreased both the MMP and neurite count,
suggesting enhanced neurotoxicity in addition to ethanol toxicity
(Figure 6F). Among these 21 negative hit compounds, we
identified spectazole and baclofen (Figure 6F).
We then aimed to assess whether the modulators of MNH
identified in the screening could exert a modulatory effect on
DNs independent of ethanol. We used 4- to 8-week-old DNs from
control iPSCs (XM001 line), re-plated them, and kept them for
5 days before ON treatment with the compounds (Figure 7A).
As negative hits from the screening, we focused on drugs that are
commonly employed in the context of AUD, such as disulfiram
and baclofen. In the screening, disulfiram decreased the MMP
and baclofen decreased both the MMP and neurite count in
ethanol-exposed neurons (Figures 6C,D, baclofen = compound
#49, disulfiram = compound #53). Using different biological
replicates and several drug doses, we found that 0.5–10 µM
disulfiram negatively affected the MMP (Figure 7B) and neuronal
outgrowth (Figures 7C–E) in the absence of ethanol. Baclofen
also negatively affected the MMP and neuronal outgrowth of
DNs at concentrations between 0.5 and 10 µM in the absence
of ethanol (Figures 7F–I). We then assessed the effect of lithium
carbonate (lithium), which was not included in the original
screen, on the MNH of DNs. Lithium is used for bipolar disorders
(Young, 2009), and it has been considered for the treatment
of AUD (Fawcett et al., 1987; Clark and Fawcett, 1989). We
found that lithium also negatively affected the MMP of human
DNs at concentrations between 2 and 5 mM in the absence
of ethanol (Figure 7J). Although neurite count was unaffected
(Figure 7K), lithium treatment significantly decreased neurite
length (Figure 7L) and branch points (Figure 7M) of human DNs
at concentrations between 2 and 5 mM in the absence of ethanol.
As a positive hit compound from the screening, we selected
flavoxate. DNs treated with 1 µM flavoxate showed increases of
the MMP (Figure 7N) and neurite arborization (Figures 7O–Q)
compared to DNs only treated with DMSO. Taken together, these
experiments confirmed some of the negative and positive hits
of the screening and suggested that by identifying compounds
counteracting neurotoxicity, it may be possible to discover
general modulators of MNH in humans.
DISCUSSION
In this study, we developed a novel method called the MNH
assay to assess the cellular health of human neurons derived from
human pluripotent stem cells. We employed the MNH assay to
dissect the neurotoxicity induced by ethanol on neuronal cultures
containing dopaminergic neurons, which have been implicated in
the development of AUD. Previous iPSC-based studies assessed
alcohol-mediated transcriptional changes in NMDA receptor
expression (Lieberman et al., 2012), in GABA receptor expression
(Lieberman et al., 2018), and in the expression of genes involved
in cholesterol homeostasis, notch signaling, and cell cycle (Jensen
et al., 2019). Ethanol exposure for 1 day or 7 days was found
to negatively influence the generation of mature neurons from
NPCs (De Filippis et al., 2016). However, the functional effects
of ethanol on mitochondrial neuronal function and neurite
outgrowth have not yet been investigated. Using the MNH assay,
we show that acute exposure to ethanol is sufficient to cause loss
of MNH, similar to what happens after 7 days of chronic ethanol
exposure. Importantly, acute ethanol-induced mitochondrial and
neuronal toxicity occurred in both DNs derived from healthy
individuals and from subjects diagnosed with AUD. Interestingly,
the latter were less sensitive to ethanol toxicity. In contrast to
previous studies, which did not focus on functional readouts,
the defects in human neurons developed at relatively high
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FIGURE 4 | Generation of patient-specific AUD-iPSCs. (A) Representative immunostaining images of pluripotency-associated markers OCT4 and TRA1-60 in
AUD-patient derived iPSCs (BIHi232, BIHi234, BIHi235, and BIHi236). We counterstained the cells using Hoechst. Scale bar: 100 µm. (B) Quantitative real-time
RT-PCR analysis of pluripotency-associated markers in AUD-iPSCs (BIHi232, BIHi234, BIHi235, and BIHi236) relative to fibroblasts (Fibs; CON2). Relative transcript
levels of each gene were calculated based on the 2−11CT method. Data were normalized to the housekeeping gene GAPDH and are presented as mean LOG2
ratios in relation to fibroblasts (mean ± SD). (C) Single nucleotide polymorphism (SNP)-based virtual karyotype of AUD-iPSCs. We compared the karyotype of the
iPSCs to the corresponding parental cells (peripheral blood mononuclear cells, PBMCs). We did not see any larger areas of insertions or deletions. Green: area with
genomic gain; red: with genomic loss; gray: area with loss of heterozygosity. Pt, patient. (D) Representative immunostaining images of AUD-iPSCs differentiated into
cells belonging to the three germ layers: mesoderm (smooth muscle actin, SMA), endoderm (SOX17), and ectoderm (PAX6). Scale bar: 100 µm.
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FIGURE 5 | Acute ethanol exposure reduces MMP and neuronal outgrowth in AUD-DNs. (A) Above: representative immunostaining images of NPC-associated
markers NESTIN and PAX6 counterstained with Hoechst in NPCs from AUD-iPSCs (BIHi232, BIHi234, BIHi235, and BIHi236). Scale bar: 100 µm. Below:
representative immunostaining images of neuron-associated marker TUJ1 and dopaminergic neuron-associated marker TH counterstained with Hoechst in
AUD-DNs (BIHi232, BIHi234, BIHi235, and BIHi236). Scale bar: 100 µm. (B) Schematic of MNH assay workflow of ethanol exposure for 1 h (acute exposure) on
AUD-DNs. (C–R) MNH assay-based quantification of MMP (C,G,K,O) and branching complexity (D–F,H–J,L–N,P–R) in 4- to 8-week-old AUD-DNs (C–F BIHi232;
G–J BIHi234; K–N BIHi235; O–R BIHi236) exposed to increasing concentrations of ethanol for 1 h (mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001; one-way
ANOVA followed by Dunnett’s multiple comparison test). Each dot represents values obtained from one well (n = 3 independent experiments) normalized to the
corresponding UT controls.
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FIGURE 6 | Proof-of-concept compound screening in human DNs exposed to ethanol. (A) Schematic MNH assay workflow for compound screening. (B) MNH
assay-based quantification of object count of DNs from control iPSCs (XM001 line) after ON treatment with 48 FDA-approved drugs (Selleckchem, z65122) and 5
AUD drugs with subsequent exposure to 1 M ethanol for 1 h (acute exposure; mean ± SD; n = 2 independent experiments). Values from each experiment were
normalized to the corresponding UT controls. The black line marks the mean of UT control. (C,D) MNH assay-based quantification of MMP (C) and neuronal profiling
(D; neurite count) after ON treatment with 48 FDA-approved drugs out of the Selleckchem library (z65122) and 5 AUD drugs with subsequent exposure to 1 M
ethanol for 1 h (acute exposure). Values from each experiment were normalized to the corresponding UT controls (mean ± SD; n = 2 independent experiments). The
black line marks the mean value of ethanol exposure (1 M, red dot). Gray circles mark the compounds that displayed no change in MMP or neurite counts. Light blue
dots in panel (C) mark positive hit compounds that increased MMP of more than 0.5 times the SD of neurons only exposed to ethanol. Dark blue dots in panel (C)
mark negative hit compounds that decreased the MMP more than 0.5 times the SD of neurons only exposed to ethanol. Light green dots in panel (D) mark positive
hit compounds that increased neurite count of more than 0.5 times the SD of neurons only exposed to ethanol. Dark green dots in panel (D) mark negative hit
compounds that decreased neurite count of more than 0.5 times the SD of neurons only exposed to ethanol. (E) Venn diagram depicting the compounds that
increased MMP (“MMP up”) and/or neuronal outgrowth (“neurite count up”) in ethanol-exposed DNs. (F) Venn diagram depicting the compounds that decreased the
MMP (“MMP down”) and/or the neuronal outgrowth (“neurite count down”) in ethanol-exposed DNs.
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FIGURE 7 | Continued
Frontiers in Cell and Developmental Biology | www.frontiersin.org 11 November 2020 | Volume 8 | Article 590540
fcell-08-590540 October 30, 2020 Time: 15:48 # 12
Zink et al. High-Throughput Mitochondrial Neuronal Health Assay
FIGURE 7 | Compounds modulating neuronal toxicity in human DNs. (A) Schematic MNH assay workflow for neuronal toxicity. (B–E) MNH assay-based
quantification of MMP (B) and neuronal profiling (C–E) including neurite count (C), neurite length (D), and branch points (E) after ON treatment of 4- to 8-week-old
DNs from control iPSCs (XM001) with increasing concentrations of disulfiram (n = 3 independent experiments; mean ± SEM; *p < 0.05, **p < 0.01; ***p < 0.001;
one-way ANOVA followed by Dunnett’s multiple comparison test). (F–I) MNH assay-based quantification of MMP (F) and neuronal profiling (G–I) including neurite
count (G), neurite length (H), and branch points (I) after ON treatment of 4- to 8-week-old DNs from control iPSCs (XM001) with increasing concentrations of
baclofen (n = 3 independent experiments; mean ± SEM; *p < 0.05, **p < 0.01; one-way ANOVA followed by Dunnett’s multiple comparison test). (J–M) MNH
assay-based quantification of MMP (J) and neuronal profiling (K–M) including neurite count (K), neurite length (L), and branch points (M) after ON treatment of 4- to
8-week-old DNs from control iPSCs (XM001) with increasing concentrations of lithium (n = 3 independent experiments; mean ± SEM; *p < 0.05, **p < 0.01;
***p < 0.001; one-way ANOVA followed by Dunnett’s multiple comparison test). (N–Q) MNH assay-based quantification of MMP (N) and neuronal profiling (O–Q)
including neurite count (O), neurite length (P), and branch points (Q) after ON treatment of 4- to 8-week-old DNs from control iPSCs (XM001) with 1 µM flavoxate
(n = 3 independent experiments; mean ± SEM; *p < 0.05, **p < 0.01; one-way ANOVA followed by Dunnett’s multiple comparison test). (R) Schematics of potential
applications of the MNH assay.
concentrations of ethanol. Nonetheless, these concentrations did
not induce widespread cell death, and the MNH assay was able
to capture an early state of cellular toxicity that may still be
reversible. Hence, the MNH assay may serve as a platform for
identifying early modulators of neurotoxicity in humans.
Using the MNH assay, we identified potential modulators of
ethanol-induced neurotoxicity. In a proof-of-concept screening
of the 53 FDA-approved drugs that are in clinical use for
brain diseases, flavoxate had positive effects on mitochondrial
health and neurite outgrowth capacity. These positive effects
also occurred in the absence of ethanol exposure. Conversely, 21
compounds showed a potential worsening effect in the presence
of ethanol. Further studies should be carried out to confirm
the exploratory results and determine the pharmacokinetic and
pharmacodynamic characteristics of the hit candidates. Our
findings suggest that the MNH assay could be used for various
applications, including disease-specific studies, neurotoxicity
studies, and studies aimed to assess the individual neuronal
susceptibility to different stimuli (Figure 7R).
Most drugs of abuse, including alcohol, have significant
neurotoxic effects (Soleimani et al., 2016). Understanding the
level of neurotoxicity caused by ethanol may enable the
development of protective drugs to reduce the risk of developing
neurodegenerative effects as consequence of excessive alcohol
consumption. Interestingly, two drugs commonly employed
in subjects with AUD, disulfiram and baclofen, negatively
modulated MNH. Their negative effects also occurred in the
absence of ethanol. Treatment with lithium, another drug that
can be employed in the context of AUD, also worsened MNH
in the absence of ethanol. These latter data are in agreement
with previous studies reporting toxic consequences of lithium
treatment (Lang and Davis, 2002; Mignarri et al., 2013; Shah et al.,
2015). Altogether, our findings on AUD drugs warrant further
exploration and raise concerns with respect to the potentially
enhanced toxicity of drugs when used in concert with alcohol
intake, which can increase neurotoxicity. In-depth analyses are
warranted to confirm the functional consequences of various
AUD treatments on human neuronal health.
The assessment of possible toxic effects of compounds is of
high importance in the drug development process. Neurotoxicity
testing commonly relies on in vivo animal studies that are
expensive and may not fully recapitulate the toxicity profile
of humans (Hartung, 2008; Schwartz et al., 2015). Recent
studies used MEA to investigate the effect of compounds on
spontaneous neuronal activity and network activity (Zwartsen
et al., 2018). Various HT screening methods have also been
established (Saunders et al., 2014; Iannetti et al., 2015; Gelles and
Chipuk, 2016; Daniele et al., 2017; Kepiro et al., 2018; Arias-
Fuenzalida et al., 2019; Varkuti et al., 2020). Nonetheless, there
is a need for additional in vitro systems centered on human
iPSC derivatives in order to capture different aspects of human
neurotoxicity (Schmidt et al., 2017). We suggest the MNH assay
as a novel HT assay centered on human pluripotent stem cell-
derived neurons that can be further multiplexed with additional
imaging-based techniques, including for example the addition of
an apoptotic dye to quantify cell death (Saunders et al., 2014;
Gelles and Chipuk, 2016). iPSC-derived 3D neural cultures may
also be employed to assess the neurotoxic potential of drugs
and environmental toxicants (Sirenko et al., 2019). Therefore,
future implementations should aim to adapt the MNH assay
to 3D culture systems, such as iPSC-derived brain organoids
(Menacho and Prigione, 2020).
Taken together, we developed a novel assay that enabled us
to capture the ethanol-induced toxicity in human DNs and to
identify potential small molecule modulators. We propose the
MNH assay as a tool for the evaluation of human neuronal health
and for conducting HT drug discovery and drug toxicity studies.
MATERIALS AND METHODS
Generation of iPSCs From PBMCs
This study was approved by the ethics committee of the
Charité – Universitätsmedizin Berlin (EA1/206/15). Patient
peripheral blood mononuclear cells (PBMCs) were obtained after
informed consent. In brief, blood collections were performed
using standard, 8 ml Vacutainer Cell Processing Tubes (both
sodium citrate and sodium heparin-based tubes are acceptable;
BD Biosciences; Franklin Lakes, NJ, United States). Samples were
processed within 24 h after blood collection by collecting the
PBMC-containing upper phase and washed with ice-cold PBS.
Cells were either frozen down or used directly for enrichment of
the erythroblast population. In brief, cell pellet of 1× 106–2× 106
PBMCs was resuspended in 2 ml erythroblast cell expansion
media containing basal blood media Stempo34 SFM (Thermo
Fisher) supplemented with 1x Stempo34 nutrient supplement
(Thermo Fisher), 1x glutamine (Thermo Fisher) and cytokines
such as 20 ng/ml IL3 (PeproTech), 20 ng/ml IL6 (PeproTech),
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100 ng/ml Flt3 (PeproTech), 100 ng/ml SCF (PeproTech), 2 U/ml
erythropoietin (EPO, Millipore) and plated in a standard 12-
well plate (2 mL/well). The media was changed every other
day and after 4 to 6 days a significant enrichment of highly
proliferating erythroblast population was observed. This highly
proliferative cell population was used for the reprogramming.
Erythroblast cells from PBMCs were reprogrammed using the
Cytotune R©-iPS 2.0 Sendai Reprogramming Kit according to the
manufacturer’s instructions. In brief, cells were transduced with
CytoTune 2.0 Sendai virus coding for OCT3/4, KLF4, SOX2, and
MYC genes with recommended MOI in 1 ml of erythroblast
cell expansion media containing 10 µg/ml polybrene (Sigma).
After 24 h of transduction the virus was removed, and cells
were cultured for further 2 days in erythroblast cell expansion
media. From day 1 to 3 the cells were cultured in repro media
1 consisting of erythroblast cell expansion media, 200 µM/L
sodium butyrate (NaB, Stem Cell Technologies) and 50 µg/ml
ascorbic acid (Sigma). On day 3 after transduction 1 × 105 cells
were plated onto mouse embryonic fibroblast (MEFs) layer or
vitronectin coated plate in repro media 1. From day 4 until day
7, the media was changed with repro media 2 containing basal
blood media, NaB and ascorbic acid without cytokines. On day 7
the media was switched to repro media 2 and E7 reprogramming
media (1:1) containing E6 basal media (Thermo Fisher) with
NaB, ascorbic acid and 100 ng/ml FGF2 (PeproTech) and the
same was used every day until day 13. From day 13 onward
the cells were cultured in E8 life (Thermo Fisher) until day 20.
Emerging colonies were picked 3 weeks after the transduction
and tested for remaining viral RNA expression using RT-PCR by
checking the expression of Sendai viral reprogramming particles
using primers specific to Sendai virus.
iPSC Culture
Control iPSCs were previously generated using episomal
plasmids and described as XM001 (Wang et al., 2018). hESC
line H1 was purchased from WiCell and was used in accordance
with the German license of AP issued by the Robert Koch
Institute (AZ: 3.04.02/0077-E01). All PSCs were cultivated
on Matrigel (BD Bioscience)-coated plates using: StemMACS
iPS-Brew XF medium (Miltenyi Biotec GmbH, #130-104-
368), supplemented with 0.1 mg/ml Pen/Strep (Thermo Fisher
Scientific) and MycoZap [1x] (Lonza). We routinely monitored
against mycoplasma contamination using PCR. 10 µM ROCK
inhibitor (Enzo, ALX-270-333-M005) was added after splitting
to promote survival. PSC cultures were kept in a humidified
atmosphere of 5% CO2 at 37◦C and 5% oxygen. All other cultures
were kept under atmospheric oxygen condition. Pluripotency of
the generated lines was confirmed following previously published
procedures (Prigione et al., 2010) using in vitro embryoid bodies
(EB)-based differentiation. We reprogrammed patient PBMCs
using Sendai viruses.
Karyotype Analysis
Briefly, genomic DNA was isolated using the DNeasy blood and
tissue kit (Qiagen, Valencia, CA, United States) and samples
were analyzed using the human Illumina OMNI-EXPRESS-
8v1.6 BeadChip. First, the genotyping was analyzed using
GenomeStudio 1 genotyping module (Illumina). Thereafter,
KaryoStudio 1.3 (Illumina) was used to perform automatic
normalization and to identify genomic aberrations utilizing
settings to generate B-allele frequency and smoothened Log R
ratio plots for detected regions. The stringency parameters used
to detect copy number variations (CNVs) were set to 75 kb
(loss), 100 kb (gain) and CN-LOH (loss of heterozygosity) regions
larger than 3 MB.
Differentiation of NPCs and DNs
We obtained NPCs and DNs using a previously published
protocol (Reinhardt et al., 2013). Briefly, PSCs were detached
from Matrigel-coated plates using StemPro R© Accutase R© Cell
Dissociation Reagent (accutase; Thermo Fisher) and the collected
sedimented cells were transferred into low-attachment petri
dishes and kept for 2 days in ES-based medium containing: KO-
DMEM [1x] (Gibco), KO-SR [1x] (Gibco), NEAA [1x] (Gibco),
2 mM L-glutamine (Gibco), 0.1 mg/ml Pen/Strep (Gibco), 1 mM
pyruvate (Gibco) and MycoZap [1x] (Lonza), supplemented
with 0.5 µM purmorphamine (PMA, Millipore), 3 µM CHIR
99021 (CHIR, Caymen Chemical), 10 µM SB-431542 (MACS
Miltenyi) and 1 µm dorsomorphin (Sigma). From day 2 to
day 4, the media was switched to N2B27 medium containing:
Neurobasal:DMEM/F12 [1:1], N2 [1:200], B27 without vitamin A
[1:100], 2 mM L-glutamine, 0.1 mg/ml Pen/Strep, 1 mM Pyruvate
and MycoZap [1x] supplemented with 0.5 µM PMA, 3 µM CHIR
99021, 10 µM SB-431542 and 1 µM dorsomorphin. On day 4
the media was switched to the final maturation media consisting
of N2B27 medium supplemented with 3 µM CHIR 99021,
0.5 µM PMA and 150 µM vitamin C (Sigma Aldrich). On day
6, the suspended cells were transferred onto Matrigel-coated well
plates and kept in the maturation media with media exchange
every 2 days. NPCs were maintained on this media without
ROCK inhibitor and used for experiments between passage 7
and 20. For neuronal differentiation, we used NPCs between
passage 7 and 13. To initiate the differentiation, the media was
changed to N2B27 (B27 with vitamin A) medium with addition
of 200 µM vitamin C, 100 ng/mL FGF8 (R&D Systems) and
1 µM PMA. After 8 days, the media condition was replaced with
N2B27 (B27 with vitamin A) media supplemented with 200 µM
vitamin C, 0.5 µM PMA, 500 µM cAMP (StemCells), 10 ng/mL
BDNF (MACS Miltenyi), 10 ng/mL GDNF (MACS Miltenyi) and
1 ng/mL TGFbeta3 (MACS Miltenyi). On day 9, cells were split
with accutase and seeded on Matrigel-coated plates in N2B27
(B27 with vitamin A) medium supplemented with 200 µM
vitamin C, 500 µM cAMP, 10 ng/mL BDNF, 10 ng/mL GDNF,
and 1 ng/mL TGFbeta3. The media was changed every 3–4 days
and the differentiated cells were kept in culture for 4 weeks up
to 8 weeks. 10 µM ROCK inhibitor (Enzo, ALX-270-333-M005)
was always added after splitting to promote survival.
PCR Analyses
Gene expression analysis was performed by quantitative real-
time RT-PCR (qRT-PCR) using SYBR Green PCR Master Mix
and the ViiATM 7 Real-Time PCR System (Applied Biosystems).
For each target gene, cDNA samples and negative controls
were measured in triplicates using 384-Well Optical Reaction
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Plates (Applied Biosystems). Relative transcript levels of each
gene were calculated based on the 2−11CT method. Data
were normalized to the housekeeping gene GAPDH and are
presented as mean LOG2 ratios in relation to control cell lines.
Primers were for OCT4 F: GTGGAGGAAGCTGACAACAA
and R: ATTCTCCAGGTTGCCTCTCA, for NANOG F: CC
TGTGATTTGTGGGCCTG and R: GACAGTCTCCGTGTG
AGGCAT, for SOX2 F: GTATCAGGAGTTGTCAAGGCAGAG
and R: TCCTAGTCTTAAAGAGGCAGCAAAC, for DNM
T3B F: GCTCACAGGGCCCGATACTT and R: GCAGTCCTG
CAGCTCGAGTTTA, for DPP4 F: TGGTGTCAGGTGGTGTG
TGG and R: CCAGGCTTGACCAGCATGAA, for VIM F:
GGAGCTGCAGGAGCTGAATG and R: GACTTGCCTTGGC
CCTTGAG, for GAPDH F: CTGGTAAAGTGGATATTGT
TGCCAT and R: TGGAATCATATTGGAACATGTAAACC.
Immunostaining
Cells grown on Matrigel-coated coverslips were fixed with
4% paraformaldehyde (PFA, Science Services) for 15 min at
room temperature (RT) and washed two times with PBS. For
permeabilization, cells were incubated with blocking solution
containing 10% normal donkey serum (DNS) and 1% Triton
X-100 (Sigma-Aldrich) in PBS with 0.05% Tween 20 (Sigma-
Aldrich) (PBS-T) for 1 h at RT. Primary antibodies were diluted
in blocking solution and incubated overnight at 4◦C on a
shaker. Primary antibodies were used as follows: PAX6 (Covance,
1:200), SOX2 (Santa Cruz, 1:100), TUJ1 (Sigma-Aldrich, 1:3000),
OCT4 (Santa Cruz, 1:300), TRA-1-60 (Millipore, 1:200), MAP2
(Synaptic System, 1:100), NANOG (R&D Systems, 1:200), SMA
(DakoCytomation, 1:200), SOX17 (R&D Systems, 1:50), TH
(Millipore, 1:300), FOXA2 (Sevenhills, 1:100). Corresponding
secondary antibodies (Alexa Fluor, 1:300, Life Technologies)
were diluted in blocking solution for 1 h at RT on a
shaker. Counterstaining of nuclei was carried out using 1:2,500
InvitrogenTM Hoechst 33342 (Hoechst; ThermoFisher). All
images were acquired using the confocal microscope LSM510
Meta (Zeiss) in combination with the AxioVision V4.6.3.0
software (Zeiss) and further processed with AxioVision software
and Photoshop CS6 version 6.2 (Adobe Systems).
Micro-Electrode Array (MEA) Recordings
Micro-electrode array recordings were conducted using the
Maestro system from Axion BioSystems. A 48-well MEA plate
with 16 electrodes per well was precoated with 1 mg/ml
polyethylenimine (PEI; Sigma Aldrich) for 1 h at RT, washed
three times with sterile H20 and air-dried ON in the cell culture
hood. Afterward, the plate was pre-coated with Matrigel by
placing a 7 µl drop of Matrigel (200 µg/ml) into the center of the
well (on top of the electrodes) and incubated for 1 h at 37◦C, 5%
CO2. Remaining coating solution was removed, and 80,000 DNs
per well were seeded on the electrodes in each well of the MEA
plate by preparing a cell suspension of 7 µl and applying a droplet
directly into the center of each well of the MEA plate. Following
an incubation of 1 h at 37◦C, 5% CO2 to ensure settlement of
the DNs, 300 µl maturation media (for media formulation see
“Differentiation of NPCs and DNs”) was slowly added to each
well. Half of the media was refreshed every 2 days. Two weeks
after plating, spontaneous activity was recorded at a sampling rate
of 12.5 kHz under controlled conditions (37◦C and 5% CO2) for
10 min on different days. Using Axion Integrated Studio (AxIS
1.4.1.9), a digital low pass filter of 4 kHz and high pass filter of
200 Hz cut-off frequency and a threshold of 5.5x the standard
deviation was set to minimize false-positives detections. Raw data
was analyzed using the Neural Metric Tool (Axion BioSystems)
to analyze spikes. Electrodes that measured more than five spikes
per minute were considered active.
High-Content Imaging (HCI)
High-content imaging-based quantification of MMP and
neuronal profiling was assessed using the HCI platform
CellInsight CX7 microscope (Thermo Fisher Scientific) and the
integrated BioApplications. Briefly, 4- to 8-week-old DNs were
split using accutase and seeded at a density of 10,000–20,000
cells/well on Matrigel-coated 96 well plates with black-wall
and clear-bottom (µClear, Greiner). The cells were live-
stained with non-quenching concentrations of 0.5 nM TMRM
(ThermoFisher) for 30 min at 37◦C, 5% CO2, and counterstained
with 1:10,000 Hoechst (Thermo Fisher). Parameters were set
as follows: primary object detection (cell nuclei) was based
on Hoechst staining, captured in channel 1. Detection of the
cellular region of interest, captured in channel 2, was based
on TMRM staining which accumulates in active mitochondria
as a result of the MMP. Changes in TMRM intensity within
the region of interest (ring region with adjusted threshold)
were quantified using the “Cellomics CellHealthProfiling v4
BioApplication” (CellInsight CX7, Thermo Fisher Scientific)
using the feature “MeanTargetAvgIntensityCh2.” Afterward,
neuronal cultures were fixed with 4% PFA for 15 min at
RT, stained with TUJ1 antibody and counter-stained with
Hoechst (see “Immunostaining” for details on staining method).
Parameters were set as follows: primary object detection (cell
nuclei) was based on Hoechst staining, captured in channel
1. Detection of the region of interest (neurites) was based
on TUJ1 staining, captured in channel 2. The morphological
changes of TUJ1-postive cells were quantified using the
“Cellomics Neuronal Profiling v4 BioApplication” (CellInsight
CX7, Thermo Fisher Scientific). Features obtained with the




apoptosis through Annexin-V intensity was assessed using the
HCI platform CellInsight CX7 microscope (Thermo Fisher
Scientific) and the integrated BioApplications. Briefly, 4- to
8-week-old DNs were split using accutase and seeded at a density
of 10,000–20,000 cells/well on Matrigel-coated 96 well plates with
black-wall and clear-bottom (µClear, Greiner). The cells were
live-stained with 5 µl Annexin V (protocol from the Annexin
V-FITC Kit by MACS Miltenyi was adapted to 2D cell culture)
per 106 cells for 30 min at 37◦C, 5% CO2 and counterstained
with 1:10,000 Hoechst (Thermo Fisher). For quantification of the
Annexin-V intensity, the TMRM intensity protocol (Cellomics
CellHealthProfiling v4 BioApplication) was modified according
to the Annexin-V staining.
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Treatment of DNs
FCCP and Ant.A, or Oligomycin were applied to 4- to 8-week-
old DNs together with the staining solution (0.5 nM TMRM
and 1:10,000 Hoechst) and incubated for 30 min at 37◦C,
5% CO2. Staining solution containing FCCP and Ant.A, or
Oligomycin was removed and DNs were washed three times
gently with 1x PBS before corresponding phenolred-free media
was applied and cells were measured at the CellInsight CX7.
Treatments with ethanol were performed 5 days after re-plating
4- to 8-week-old DNs on black-wall, round bottom 96-well
plates (µClear, Greiner). 99.5% ethanol (v/v; Roth) was pre-
diluted in culture media as 5 M stock solution freshly before
use. Accordingly, 10 mM–2.5 M ethanol was further diluted in
phenolred-free culture media and administered to the DNs. For
the chronic ethanol exposure, freshly prepared culture media
containing ethanol was changed every other day at the same
time for 7 days including 1 day of withdrawal. Evaporation
of ethanol following daily media changes in unsealed culture
plates may provide a pattern of exposure more similar to alcohol
consumption observed in human daily heavy drinkers. After
7 days of ethanol exposure, DNs were stained with TMRM
and Hoechst (see details above). Following the removal of the
staining solution, phenolred-free media containing ethanol was
reapplied and incubated again for 1 h before assessment of the
MNH at the CellInsight CX7. For the acute ethanol exposure,
DNs were first stained with TMRM and Hoechst (see details
above) before freshly prepared phenolred-free culture medium
containing ethanol was administered to the DNs for 1 h at 37◦C,
5% CO2. After the incubation time, DNs where immediately
processed at the CellInsight CX7. Drug treatment (flavoxate,
disulfiram, baclofen and lithium) was performed on 4- to 8-
week-old DNs with incubation ON at 37◦C, 5% CO2. The next
day, staining solution containing 0.5 nM TMRM and 1:10,000
Hoechst was added to the media for 30 min at 37◦C, 5% CO2.
Further processing was performed according to the MNH assay
as described before.
Compound Screening – MNH Assay
For the proof-of-concept compound screening, 48 compounds
were selected from a library of 700 FDA-approved drugs
(Selleckchem- z65122) and 5 drugs were added, used in the
context of AUD treatment (Appendix Table 1). Briefly, 10,000–
20,000 DNs/well were plated on black-wall, round bottom 96-well
plates (µClear, Greiner) 5 days before adding the compounds
ON. Compounds were used in a final concentration of 0.5 µM
diluted in culture media. DMSO concentration was diluted down
below 0.05%. The second day, DNs were stained with 0.5 nM
TMRM together with 1:10,000 Hoechst diluted in phenol red-
free culture medium for 30 min at 37◦C, 5% CO2 by adding
the staining solution into the media containing the drugs. After
removal of the staining solution, compounds together with 1 M
ethanol were applied to the DNs and incubated for 1 h at
37◦C, 5% CO2. Control wells included DNs kept untreated and
DNs exposed to 1 M ethanol only. HCI was conducted with
the CellInsight CX7 microscope (Thermo Fisher) and analyzed
according to the “CellHealth Profiling” and “Neuronal Profiling”
BioApplication. The same screening was repeated twice, and the
values shown in Figures 6B–D represent the mean values of the
two runs (mean,±SD).
Statistical Analysis
Data were analyzed using GraphPad-Prism software (Prism
4.0, GraphPad Software, Inc.). Data presentation and respective
statistical analysis of each individual graph are described in the
respective figure legends. The z-factor is defined as the means (µ)
and standard deviations (σ) of both the positive (p) and negative
(n) controls as follows:
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TABLE A1 | List of selected compounds from the FDA-approved drug screening library (z65122).
APPENDIX
Compound # Name M.w. Target Indication Brief description CAS number MMP rel. to
UT (value)
Neurite count
rel. to UT (value)
1 Bethanechol
chloride
196.68 AChR Neurological disease Selective muscarinic receptor agonist
without any effect on nicotinic receptors






Neurological disease Ca2+ channel blocker, used as an
antifungal medicine that fights infections
caused by fungus
24169-02-6 Down (0.761) Down (0.701)
3 Acetanilide
(Antifebrin)
135.16 n.d. Neurological disease Aniline derivative and has possess
analgesic
103-84-4 Down (0.630) Down (0.761)
4 Cefprozil hydrate
(Cefzil)
407.44 n.d. Neurological disease Second-generation cephalosporin type
antibiotic




475.57 AChR Neurological disease Tartrate salt of tolterodine that is a
competitive muscarinic receptor antagonist






Neurological disease Potent, second-generation, selective,
histamine antagonist




167.59 n.d. Neurological disease Intermediate in heme biosynthesis in the
body and the universal precursor of
tetrapyrroles
5451-09-2 Down (0.697) Down (0.845)
8 Ronidazole 200.15 Anti-infection Neurological disease Antiprotozoal agent 7681-76-7 Down (0.709) Down (0.799)
9 Miglitol (Glyset) 207.22 Carbohydrate
metabolism
Neurological disease Oral anti-diabetic drug 72432-03-2 Down (0.786) Normal (0.894)
10 Buflomedil HCl 343.85 Adrenergic
receptor
Neurological disease Vasodilator used to treat claudication or the
symptoms of peripheral arterial disease
35543-24-9 Down (0.529) Up (1.066)
11 PCI-32765
(Ibrutinib)
440.5 Src Neurological disease Potent and highly selective Btk inhibitor with 936563-96-1 Down (0.652) Down (0.814)
12 Amoxicillin
(Amoxycillin)
365.4 Anti-infection Neurological disease Moderate-spectrum, bacteriolytic, β-lactam
antibiotic





Neurological disease Semi-synthetic derivative of a natural taxoid 183133-96-2 Down (0.768) Down (0.889)
14 Niclosamide
(Niclocide)
327.12 STAT Neurological disease Inhibits DNA replication and inhibits STAT 50-65-7 Down (0.728) Down (0.812)
15 Lurasidone HCl 529.14 Dopamine
receptor
Neurological disease Antipsychotic, inhibits dopamine D2,
5-HT2A, 5-HT7, 5-HT1A and noradrenaline
α2C
367514-88-3 Down (0.804) Down (0.877)
16 D-Phenylalanine 165.19 n.d. Neurological disease Carboxypeptidase A, endorphinase and
enkephalinase inhibitor, enhances
endorphin production and diminishes pain
673-06-3 Down (0.731) Down (0.871)
17 Palonosetron HCl 332.87 5-HT receptor Neurological disease 5-HT3 antagonist used in the prevention
and treatment of chemotherapy-induced
nausea and vomiting









































TABLE A1 | Continued
Compound # Name M.w. Target Indication Brief description CAS number MMP rel. to
UT (value)
Neurite count
rel. to UT (value)
18 Azelnidipine 582.65 Calcium
channel
Neurological disease Dihydropyridine calcium channel blocker 123524-52-7 Down (0.682) Down (0.872)
19 Dexmedetomidine 200.28 Adrenergic
receptor
Neurological disease Sedative medication used by intensive care
units and anesthetists





Neurological disease Non-nucleoside reverse transcriptase
inhibitor (NNRTI) used for the treatment of
HIV
269055-15-4 Normal (0.904) Normal (0.921)
21 Oxybutynin
chloride
393.95 AChR Neurological disease Anticholinergic medication used to relieve
urinary and bladder difficulties





Neurological disease H1 antagonist, inhibiting PhIP
glucuronidation
154-69-8 Up (0.960) Up (1.146)
23 Articaine HCl 320.84 n.d. Neurological disease Dental local anesthetic which contains an
additional ester group that is metabolized
by esterases in blood and tissue





Neurological disease Competitively inhibits histamine at H1
receptors with substantial sedative and
anticholinergic effects
562-10-7 Down (0.755) Normal (0.912)
25 Atomoxetine HCl 291.82 5-HT receptor Neurological disease Selective norepinephrine (NE) transporter
inhibitor with Ki of 5 nM, with 15- and
290-fold lower affinity for human 5-HT and
DA transporters
82248-59-7 Normal (0.910) Normal (0.955)
26 Brinzolamide 383.51 Carbonic
anhydrase
Neurological disease Potent carbonic anhydrase II inhibitor 138890-62-7 Normal (0.850) Normal (0.934)
27 Ropinirole HCl 296.84 Dopamine
receptor
Neurological disease Selective dopamine D2 receptors inhibitor 91374-20-8 Down (0.791) Low (0.886)
28 Azlocillin sodium
salt
484.48 Anti-infection Neurological disease Acylampicillin with a broad spectrum
against bacteria
37091-65-9 Up (0.935) Normal (0.956)
29 Azacyclonol 267.37 5-HT receptor Neurological disease Drug used to diminish hallucinations in
psychotic individuals
115-46-8 Up (0.955) Normal (0.940)
30 Reboxetine
mesylate
409.5 n.d. Neurological disease Norepinephrine reuptake inhibitor 98769-84-7 Normal (0.899) Down (0.887)
31 Meptazinol HCl 269.81 Opioid receptor Neurological disease Opioid analgesic, which inhibits
[3H]dihydromorphine binding
59263-76-2 Normal (0.891) Down (0.880)
32 Nalmefene HCl 375.89 Anti-infection Neurological disease Naltrexone analog with opioid antagonistic
property
58895-64-0 Up (0.964) Down (0.886)
33 Amidopyrine 231.29 n.d. Neurological disease Analgesic, anti-inflammatory, and
antipyretic properties
58-15-1 Normal (0.854) Normal (0.901)
34 Moclobemide 268.74 MAO Neurological disease MAO-A (5-HT) inhibitor 71320-77-9 Up (0.952) Down (0.862)
35 Lithocholic acid 376.57 FXR Neurological disease Acts as a detergent to solubilize fats for
absorption
434-13-9 Normal (0.859) Down (0.888)
36 Ethambutol HCl 277.23 Anti-infection Neurological disease Bacteriostatic antimycobacterial agent,
which obstructs the formation of cell wall by
inhibiting arabinosyl transferases









































TABLE A1 | Continued




37 Acebutolol HCl 372.89 Adrenergic
receptor
Neurological disease β-Adrenergic receptors antagonist used
in the treatment of hypertension, angina
pectoris and cardiac arrhythmias
34381-68-5 Up (0.943) Normal (0.957)
38 Hyoscyamine
(Daturine)





Neurological disease Inhibitor of sodium channel, NMDA
receptor and nAChR with IC50 of
60 µM, 0.296 mM and 45.5 µM, which
is also an inhibitor of 5-HT3 with KD of
1.7 µM
51-05-8 Normal (0.886) Down (0.846)




Neurological disease Anticholinergic tertiary amine 67-92-5 Normal (0.924) Down (0.877)
41 Flavoxate HCl 427.92 AChR Neurological disease Muscarinic AChR antagonist 3717-88-2 Up (1.018) Up (1.005)
42 Aclidinium bromide 564.55 AChR Neurological disease Human muscarinic AChR M1, M2, M3,
M4, and M5
320345-99-1 Down (0.789) Up (1.050)
43 Bismuth
subsalicylate
362.09 COX Neurological disease Active ingredient in Pepto-Bismol and
inhibits prostaglandin G/H synthase 1/2
14882-18-9 Normal (0.899) Normal (0.910)
44 Diphemanil
methylsulfate
389.51 AChR Neurological disease Quaternary ammonium anticholinergic,
it binds muscarinic acetylcholine
receptors (mAchR)
62-97-5 Up (0.970) Down (0.881)
45 Doxapram HCl 432.98 TASK-1,
TASK-3, TASK-
1/TASK-3
Neurological disease TASK-1, TASK-3, TASK-1/TASK-3
heterodimeric channel function
7081-53-0 Up (0.958) Down (0.886)
46 Methazolamide 236.27 Carbonic
anhydrase
Neurological disease Carbonic anhydrase inhibitor 554-57-4 Normal (0.885) Down (0.884)





Neurological disease Anticonvulsant of the pyrimidinedione
class
125-33-7 Up (0.961) Down (0.858)
49 Baclofen 213,661 GABA receptor AUD drug Derivative of the neurotransmitter
γ-aminobutyric acid (GABA)
1134-47-0 Down (0.631) Down (0.726)
50 Naltrexone
hydrochloride
341.401 Opioid receptor AUD drug N-cyclopropylmethyl derivative of
oxymorphone. Competitive antagonists
at the µ-opioid receptor (MOR)
16590-41-3 Down (0.750) Down (0.790)
51 Acamprosate
calcium
181.211 GABA receptor AUD drug NMDA receptor antagonist and positive
allosteric modulator of GABAA
receptors
77337-76-9 Down (0.814) Down (0.888)
52 Clomethiazole
hydrochloride
161.653 GABA receptor AUD drug Positive allosteric modulator at the
barbiturate/picrotoxin site of the
GABAA receptor
533-45-9 Up (0.992) Normal (0.906)
53 Disulfiram 296.52 Dehydrogenase AUD drug Inhibitor of the enzyme acetaldehyde
dehydrogenase
97-77-8 Down (0.734) Normal (0.912)
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